BROOKSPharmaceuticals
Brooks Laboratories Ltd — Cash Flow Statement
₹37.11
-7.63%
Brooks Laboratories Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Depreciation | 1.60 Cr | 1.77 Cr | 7.03 Cr | 7.35 Cr | — |
| Free Cash Flow | 1.60 Cr | -10.24 Cr | -14.96 Cr | -60.66 Cr | — |
| Issuance Of Capital Stock | 42.50 Cr | 11.27 Cr | 0.00 | 0.00 | — |
| Capital Expenditure | -0.92 Cr | -0.44 Cr | -0.47 Cr | -23.22 Cr | — |
| End Cash Position | 0.04 Cr | 0.13 Cr | 0.02 Cr | 2.60 Cr | — |
| Beginning Cash Position | 0.13 Cr | 0.02 Cr | 2.60 Cr | 0.88 Cr | — |
| Changes In Cash | -0.08 Cr | 0.10 Cr | -2.58 Cr | 1.72 Cr | — |
| Financing Cash Flow | 43.36 Cr | 9.72 Cr | 11.41 Cr | 64.07 Cr | — |
| Interest Paid Cff | -0.83 Cr | -0.68 Cr | -2.18 Cr | -3.10 Cr | — |
| Net Common Stock Issuance | 42.50 Cr | 11.27 Cr | 0.00 | 0.00 | — |
| Common Stock Issuance | 42.50 Cr | 11.27 Cr | 0.00 | 0.00 | — |
| Net Issuance Payments Of Debt | 1.02 Cr | -0.62 Cr | -3.84 Cr | -7.17 Cr | — |
| Net Long Term Debt Issuance | 1.02 Cr | -0.62 Cr | -3.84 Cr | -7.17 Cr | — |
| Investing Cash Flow | -45.97 Cr | 0.18 Cr | 0.49 Cr | -24.91 Cr | — |
| Interest Received Cfi | 0.07 Cr | 0.10 Cr | 0.09 Cr | 0.09 Cr | — |
| Dividends Received Cfi | 40000.00 | 40000.00 | 40000.00 | 30000.00 | — |
| Net Investment Purchase And Sale | -1.47 Cr | 0.52 Cr | 0.87 Cr | -0.30 Cr | — |
| Purchase Of Investment | -1.47 Cr | 0.00 | — | -0.30 Cr | 0.00 |
| Net Business Purchase And Sale | -43.66 Cr | 0.00 | — | 0.00 | 0.00 |
| Purchase Of Business | -43.66 Cr | 0.00 | — | 0.00 | 0.00 |
| Net PPE Purchase And Sale | -0.91 Cr | -0.44 Cr | -0.47 Cr | -20.31 Cr | — |
| Sale Of PPE | 95000.00 | 0.00 | 0.00 | 2.91 Cr | — |
| Purchase Of PPE | -0.92 Cr | -0.44 Cr | -0.47 Cr | -23.22 Cr | — |
| Operating Cash Flow | 2.52 Cr | -9.80 Cr | -14.49 Cr | -37.44 Cr | — |
| Taxes Refund Paid | 0.51 Cr | 0.20 Cr | -0.15 Cr | -0.26 Cr | — |
| Change In Working Capital | -2.63 Cr | -13.08 Cr | 11.43 Cr | -24.33 Cr | — |
| Change In Other Current Liabilities | 0.77 Cr | -0.14 Cr | 0.13 Cr | -9.56 Cr | — |
| Change In Other Current Assets | 1.00 Cr | -2.09 Cr | -0.93 Cr | -3.70 Cr | — |
| Change In Payable | -4.96 Cr | -7.89 Cr | 10.84 Cr | -2.70 Cr | — |
| Change In Inventory | 0.41 Cr | 1.69 Cr | 3.29 Cr | -3.92 Cr | — |
| Change In Receivables | -0.07 Cr | -3.38 Cr | -2.69 Cr | -5.01 Cr | — |
| Other Non Cash Items | 3.43 Cr | -0.06 Cr | 2.25 Cr | 2.79 Cr | — |
| Provisionand Write Offof Assets | -3.60 Cr | -0.16 Cr | 0.39 Cr | 0.93 Cr | — |
| Depreciation And Amortization | 1.60 Cr | 1.77 Cr | 7.03 Cr | 7.35 Cr | — |
| Gain Loss On Investment Securities | -0.01 Cr | -0.01 Cr | -0.01 Cr | -30000.00 | — |
| Net Foreign Currency Exchange Gain Loss | -11000.00 | -0.02 Cr | 5000.00 | 0.22 Cr | — |
| Gain Loss On Sale Of PPE | -95000.00 | 0.00 | 0.00 | -0.13 Cr | — |
| Net Income From Continuing Operations | -9.79 Cr | -19.57 Cr | -38.37 Cr | -23.90 Cr | — |
| Sale Of Investment | — | 0.52 Cr | — | — | 0.31 Cr |
| Amortization Cash Flow | — | 0.15 Cr | — | — | — |
| Gain Loss On Sale Of Business | — | 0.00 | -0.36 Cr | — | — |
| Other Cash Adjustment Outside Changein Cash | — | — | -1000.00 | -1000.00 | -1000.00 |
| Net Other Financing Charges | — | — | 17.63 Cr | 74.42 Cr | 1000.00 |
| Net Other Investing Changes | — | — | 1000.00 | -4.40 Cr | -1000.00 |
| Pension And Employee Benefit Expense | — | — | -0.04 Cr | 0.03 Cr | 0.11 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Brooks Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.